Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cardioprotection Conferred by Sitagliptin Is Associated with Reduced Cardiac Angiotensin II/Angiotensin-(1-7) Balance in Experimental Chronic Kidney Disease
Juliana Isa Beraldo, Acaris Benetti, Flávio A. Borges-Júnior, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 8, pp. 1940-1940
Open Access | Times Cited: 34

Showing 1-25 of 34 citing articles:

COVID‐19 and comorbidities: A role for dipeptidyl peptidase 4 (DPP4) in disease severity?
Margaret F. Bassendine, Simon H. Bridge, Geoffrey W. McCaughan, et al.
Journal of Diabetes (2020) Vol. 12, Iss. 9, pp. 649-658
Open Access | Times Cited: 145
DPP4 and ACE2 in Diabetes and COVID-19: Therapeutic Targets for Cardiovascular Complications?
Inés Valencia, Concepción Peiró, Óscar Lorenzo, et al.
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 95
Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System
Soraya Puglisi, Alessandro Rossini, Roberta Poli, et al.
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 89
FGF23-Mediated Activation of Local RAAS Promotes Cardiac Hypertrophy and Fibrosis
Ineke Böckmann, Jonas Lischka, Beatrice Richter, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 18, pp. 4634-4634
Open Access | Times Cited: 88
Effect of linagliptin plus insulin in comparison to insulin alone on metabolic control and prognosis in hospitalized patients with SARS-CoV-2 infection
Rodolfo Guardado‐Mendoza, Miguel Angel Garcia-Magaña, Liz Jovanna Martínez-Navarro, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 20
Angiotensin-Converting Enzyme 2 Expression and Severity of SARS-CoV-2 Infection
Sarah Alabsi, Atharva Dhole, Sameh Hozayen, et al.
Microorganisms (2023) Vol. 11, Iss. 3, pp. 612-612
Open Access | Times Cited: 12
Effects of oral antidiabetic agents on the renin–angiotensin–aldosterone system
Xifeng Yang, Yijie Qi, Jinxuan Hao, et al.
European Journal of Clinical Pharmacology (2025)
Closed Access
Bidirectional relation between dipeptidyl peptidase 4 and angiotensin II type I receptor signaling
Flavia L. Martins, João Carlos Ribeiro-Silva, Ravi Nistala, et al.
AJP Cell Physiology (2024) Vol. 326, Iss. 4, pp. C1203-C1211
Closed Access | Times Cited: 3
The impact of DPP-4 inhibitors on cardiovascular disease treatment: a comprehensive review of current therapeutic strategies and future directions
Toka Elemary, Mina Nicola, Mohamed E. A. Abdelrahim, et al.
Molecular Biology Reports (2025) Vol. 52, Iss. 1
Closed Access
Sitagliptin protects liver against aflatoxin B1‐induced hepatotoxicity through upregulating Nrf2/ARE/HO‐1 pathway
Yujiang Ji, Sanatkumar Bharamu Nyamagoud, Nagaraja Sreeharsha, et al.
BioFactors (2019) Vol. 46, Iss. 1, pp. 76-82
Closed Access | Times Cited: 29
Lisinopril prevents bullous pemphigoid induced by dipeptidyl peptidase 4 inhibitors via the Mas receptor pathway
Keisuke Nozawa, Takahide Suzuki, Gen Kayanuma, et al.
Frontiers in Immunology (2023) Vol. 13
Open Access | Times Cited: 7
Dipeptidyl peptidase 4 inhibition rescues PKA-eNOS signaling and suppresses aortic hypercontractility in male rats with heart failure
Milene Tavares Fontes, Daniel F. Arruda-Junior, Danúbia Silva dos Santos, et al.
Life Sciences (2023) Vol. 323, pp. 121648-121648
Closed Access | Times Cited: 7
DPP‐4 inhibitor sitagliptin treatment results in altered myocardial metabolic proteome and oxidative phosphorylation in a swine model of chronic myocardial ischemia
Dwight D. Harris, Sharif A. Sabe, Mark Broadwin, et al.
Physiological Reports (2024) Vol. 12, Iss. 5
Open Access | Times Cited: 2
Biological Context Linking Hypertension and Higher Risk for COVID-19 Severity
Caio A.M. Tavares, Matthew A. Bailey, Adriana Castello Costa Girardi
Frontiers in Physiology (2020) Vol. 11
Open Access | Times Cited: 17
Alterations of sodium-hydrogen exchanger 1 function in response to SGLT2 inhibitors: what is the evidence?
Surasak Wichaiyo, Nakkawee Saengklub
Heart Failure Reviews (2022) Vol. 27, Iss. 6, pp. 1973-1990
Closed Access | Times Cited: 11
Unraveling the interplay between dipeptidyl peptidase 4 and the renin-angiotensin system in heart failure
Daniel F. Arruda-Junior, Thiago A. Salles, Flavia L. Martins, et al.
Life Sciences (2022) Vol. 305, pp. 120757-120757
Closed Access | Times Cited: 10
Urinary DPP4 correlates with renal dysfunction, and DPP4 inhibition protects against the reduction in megalin and podocin expression in experimental CKD
Acaris Benetti, Flavia L. Martins, Letícia de Barros Sene, et al.
AJP Renal Physiology (2020) Vol. 320, Iss. 3, pp. F285-F296
Closed Access | Times Cited: 16
Sitagliptin Repositioning in SARS-CoV-2: Effects on ACE-2, CD-26, and Inflammatory Cytokine Storms in the Lung
Farzaneh Dastan, Atefeh Abedini, Shahram Shahabi, et al.
Iranian Journal of Allergy Asthma and Immunology (2020)
Open Access | Times Cited: 13
Vitamin D3 potentiates the renoprotective effects of vildagliptin in a rat model of fructose/salt-induced insulin resistance
Nehal S. Wahba, Rasha H. Abdel‐Ghany, Salah A. Ghareib, et al.
European Journal of Pharmaceutical Sciences (2019) Vol. 144, pp. 105196-105196
Closed Access | Times Cited: 13
Incretin-based therapies and renin-angiotensin system: Looking for new therapeutic potentials in the diabetic milieu
Habib Yaribeygi, Mina Maleki, Thozhukat Sathyapalan, et al.
Life Sciences (2020) Vol. 256, pp. 117916-117916
Open Access | Times Cited: 12
Cardiovascular protection by DPP-4 inhibitors in preclinical studies: an updated review of molecular mechanisms
Esraa M. Zakaria, Walaa M. Tawfeek, Mohamed H. Hassanin, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2022) Vol. 395, Iss. 11, pp. 1357-1372
Open Access | Times Cited: 8
Revolutionizing Treatment Strategies for Autoimmune and Inflammatory Disorders: The Impact of Dipeptidyl-Peptidase 4 Inhibitors
Kashif Rahim, Muhammad Shan, Ihtisham Ul Haq, et al.
Journal of Inflammation Research (2024) Vol. Volume 17, pp. 1897-1917
Open Access | Times Cited: 1
Unraveling the Cardiac Matrix: From Diabetes to Heart Failure, Exploring Pathways and Potential Medications
Bogdan-Sorin Tudurachi, Larisa Anghel, Andreea Tudurachi, et al.
Biomedicines (2024) Vol. 12, Iss. 6, pp. 1314-1314
Open Access | Times Cited: 1
Dipeptidyl Peptidase 4 Inhibitor Linagliptin Improves Fibrosis, Apoptosis and Cardiac Function in a Large Animal Model of Chronic Myocardial Ischemia
Dwight D. Harris, Chris Stone, Mark Broadwin, et al.
Journal of Pharmacology and Experimental Therapeutics (2024) Vol. 392, Iss. 2, pp. 100532-100532
Closed Access | Times Cited: 1
Dipeptidyl peptidase 4 inhibitors in COVID-19: Beyond glycemic control
Niya Narayanan, Dukhabandhu Naik, Jayaprakash Sahoo, et al.
World Journal of Virology (2022) Vol. 11, Iss. 6, pp. 399-410
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top